Structure basis of CFTR folding, function and pharmacology
Hwang, Tzyh-Chang; Braakman, Ineke; van der Sluijs, Peter; Callebaut, Isabelle
(2023) Journal of Cystic Fibrosis, volume 22, issue S1, pp. S5 - S11
(Article)
Abstract
The root cause of cystic fibrosis (CF), the most common life-shortening genetic disease in the Caucasian population, is the loss of function of the CFTR protein, which serves as a phosphorylation-activated, ATP-gated anion channel in numerous epithelia-lining tissues. In the past decade, high-throughput drug screening has made a significant stride
... read more
in developing highly effective CFTR modulators for the treatment of CF. Meanwhile, structural-biology studies have succeeded in solving the high-resolution three-dimensional (3D) structure of CFTR in different conformations. Here, we provide a brief overview of some striking features of CFTR folding, function and pharmacology, in light of its specific structural features within the ABC-transporter superfamily. A particular focus is given to CFTR's first nucleotide-binding domain (NBD1), because folding of NBD1 constitutes a bottleneck in the CFTR protein biogenesis pathway, and ATP binding to this domain plays a unique role in the functional stability of CFTR. Unraveling the molecular basis of CFTR folding, function, and pharmacology would inspire the development of next-generation mutation-specific CFTR modulators.
show less
Download/Full Text
Keywords: ABC transporter, CFTR, corrector, modulator, potentiator, Taverne, Pediatrics, Perinatology, and Child Health, Pulmonary and Respiratory Medicine
ISSN: 1569-1993
Publisher: Elsevier bedrijfsinformatie b.v.
Note: Funding Information: The authors acknowledge funding from i) NIH (NIHR01:DK55835); the Cystic Fibrosis Foundation (grant Hwang19G0), Ministry of Science and Technology, Taiwan (109–2320-B-010–049-MY2), and Veterans General Hospitals and University System of Taiwan Joint Research Program, Taiwan (VGHUST111-G6–10–1) (to TCH), ii) Cystic Fibrosis Foundation (CFF; BRAAKM14XX0, BRAAKM18G0), the Dutch Research Council (NWO; 731.016.403), the Netherlands Cystic Fibrosis Foundation (HIT-CF 2.0), and Stichting Zeldzame Ziekte Fonds via Stichting Muco & Friends (to IB/PvdS), iii) the French association Vaincre La Mucoviscidose (to IC). Funding Information: The authors acknowledge funding from i) NIH (NIHR01:DK55835); the Cystic Fibrosis Foundation (grant Hwang19G0), Ministry of Science and Technology, Taiwan (109–2320-B-010–049-MY2), and Veterans General Hospitals and University System of Taiwan Joint Research Program, Taiwan (VGHUST111-G6–10–1) (to TCH), ii) Cystic Fibrosis Foundation (CFF; BRAAKM14XX0, BRAAKM18G0), the Dutch Research Council (NWO; 731.016.403), the Netherlands Cystic Fibrosis Foundation (HIT-CF 2.0), and Stichting Zeldzame Ziekte Fonds via Stichting Muco & Friends (to IB/PvdS), iii) the French association Vaincre La Mucoviscidose (to IC). This paper is part of a supplement supported by the European Cystic Fibrosis Society (ECFS). Publisher Copyright: © 2022
(Peer reviewed)